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Abstract
Background: Hypertensive disorders, i.e. pregnancy induced hypertension and preeclampsia,
complicate 10 to15% of all pregnancies at term and are a major cause of maternal and perinatal
morbidity and mortality. The only causal treatment is delivery. In case of preterm pregnancies
conservative management is advocated if the risks for mother and child remain acceptable. In
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contrast, there is no consensus on how to manage mild hypertensive disease in pregnancies at term.
Induction of labour might prevent maternal and neonatal complications at the expense of increased
instrumental vaginal delivery rates and caesarean section rates.
Methods/Design: Women with a pregnancy complicated by pregnancy induced hypertension or
mild preeclampsia at a gestational age between 36+0 and 41+0 weeks will be asked to participate in
a multi-centre randomised controlled trial. Women will be randomised to either induction of
labour or expectant management for spontaneous delivery. The primary outcome of this study is
severe maternal morbidity, which can be complicated by maternal mortality in rare cases.
Secondary outcome measures are neonatal mortality and morbidity, caesarean and vaginal
instrumental delivery rates, maternal quality of life and costs. Analysis will be by intention to treat.
In total, 720 pregnant women have to be randomised to show a reduction in severe maternal
complications of hypertensive disease from 12 to 6%.
Discussion: This trial will provide evidence as to whether or not induction of labour in women
with pregnancy induced hypertension or mild preeclampsia (nearly) at term is an effective
treatment to prevent severe maternal complications.
Trial Registration: The protocol is registered in the clinical trial register number
ISRCTN08132825.
Background
Pregnancy induced hypertension and preeclampsia are
common complications of pregnancy [1]. In many cases,
the clinical presentation is mild, consisting only of mild
hypertension and/or mild proteinuria at term. In other
cases however, severe maternal and fetal complications
such as eclampsia, abruptio placentae, preterm delivery,
the Hemolysis Elevated Liver enzymes and Low Platelet
count syndrome (HELLP), fetal growth restriction or even
intra-uterine fetal death may occur. Hypertensive disor-
ders in pregnancy make a major contribution to maternal
and neonatal mortality. In the Netherlands, hypertensive
disorders in pregnancy are the largest single cause of
maternal mortality [2].
Approximately 10% to 15% of all pregnancies are compli-
cated by hypertensive disorders. The vast majority of these
cases occur after 32 weeks. The only causal treatment of
the disease is delivery. In case of preterm pregnancies (28–
34 weeks gestational age) complicated by preeclampsia
expectant monitoring is advocated to increase the chance
of fetal maturity, as long as the risks for the mother remain
acceptable [3-5]. Expectant management reduces neonatal
complications and duration of neonatal stay in the inten-
sive care unit in preterm pregnancies and is not associated
with an increase in maternal complications [4,5].
In case of pregnancy induced hypertension or preeclamp-
sia at term, the situation is different from preterm disease.
In women with mild preeclampsia complications such as
abruptio placenta and small for gestational age are similar
to normotensive pregnancies. It is unclear whether in this
situation expectant management is beneficial for the
mother and her baby, since evidence is lacking. Despite
this lack of evidence delivery is often recommended
because of the unpredictability of the disease [4,6]. Recent
observational studies indicate that the onset of mild ges-
tational hypertension or mild preeclampsia at or near
term is associated with minimal to low maternal and neo-
natal morbidity [6-8]. Despite the lack of evidence that
would justify intervention, many obstetricians induce
labour in women at term with pregnancy-induced hyper-
tension or preeclampsia. Such a policy may increase the
risk of assisted vaginal delivery and caesarean section,
thus generating additional morbidity and costs [9-11]. On
the other hand, expectant management might lead to
severe pregnancy complications like eclampsia, severe
hypertension, HELLP syndrome, organ failure or an
adverse neonatal outcome.
Data from the Dutch National Obstetric Registration from
2002 showed that the yearly number of patients with
hypertension (blood pressure [BP] diastolic above 90
mmHg) without proteinuria at term is 17.000. Moreover,
there are 2.000 women with preeclampsia at term. The
lack of consensus is demonstrated by the fact that in 9.000
women with pregnancy induced hypertension or preec-
lampsia labour was induced, whereas labour started spon-
taneously in 10.000 women. Moreover, national data
indicate no impact of induction of labour on neonatal
outcome. In 2002 and 2003, the rate of babies born with
a 5-minute Apgar score below 7 was 1.3% among women
that delivered after a spontaneous onset of labour, versus
1.6% among women in whom labour was induced (OR
1.2 95% CI 1.0 to 1.5). After adjustment for potential con-
founders such as fetal weight, proteinuria and diastolic
blood pressure, this difference became statically insignifi-
cant despite the analysis of over 35.000 patients (OR 1.1BMC Pregnancy and Childbirth 2007, 7:14 http://www.biomedcentral.com/1471-2393/7/14
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95% CI 0.98 to 1.2). Since this equivalence is also
expected from the pathophysiological background of the
problem as well as from the medical literature, we antici-
pate no differences in neonatal outcome between both
strategies.
Data from the Dutch National Obstetric Registration from
Januari 2000 until Januari 2005 show that 38.170 nulli-
para had a singleton pregnancy in cephalic presentation
complicated with pregnancy induced hypertension or
preeclampsia. In 18.012 women labour started spontane-
ously, whereas in 18.810 labour was induced. The non-
elective caesarean section rate among women in whom
labour started spontaneously was 14% and among
women in whom labour was induced this rate was 22%
(OR 1,7 95% CI 1,6 to 1,8). The vaginal instrumental
delivery rates among these groups were 28% and 24%
(OR 0,88 95% CI 0,84 to 0,93).
At present, there is no evidence on the effectiveness and
efficiency of induction of labour in women with preg-
nancy induced hypertension or mild preeclampsia
(nearly) at term as compared with expectant management
with close monitoring. In post term women and women
with ruptured membranes at term, randomised trials have
indicated that induction of labour does not increase the
instrumental delivery rate [12,13]. However, the fact that
the women were post term, might implicate that myome-
trial gapjunctions facilitating effective contractions were
present [12]. These data can not be extrapolated to
women who are (nearly) at term with pregnancy induced
hypertension or preeclampsia.
In view of this clinical dilemma, we propose a ran-
domised clinical trial in which a policy of induction of
labour, if necessary preceded by artificial cervical ripening,
is compared with a policy of careful expectant monitoring
in women with pregnancy induced hypertension or mild
preeclampsia (nearly) at term. At present – to our knowl-
edge – no clinical study has been published or undertaken
to investigate this issue.
Methods/Designs
Aims
The aim of this study is to investigate whether planned
induction of labour compared with expectant manage-
ment in women with pregnancy induced hypertension or
mild preeclampsia at term will reduce severe maternal
morbidity. We hypothesize that induction of labour will
reduce maternal morbidity and mortality. The study will
also provide insight on whether induction of labour in
women with pregnancy induced hypertension or preec-
lampsia (nearly) at term will reduce costs and improve
quality of life as compared to expectant monitoring.
The proposed research concerns a multi-centre ran-
domised controlled clinical trial in women who have
pregnancy induced hypertension or mild preeclampsia at
gestational ages between 36+0 and 41+0 weeks. This study
is set in a national Obstetric Research Consortium, in
which 40 obstetric clinics in the Netherlands collaborate.
Approximately 40 clinics, including academic hospitals,
non-academic teaching hospitals and non-teaching hospi-
tals will participate in this trial.
Participants/Eligibility criteria
Patients 18 years of age or older will be eligible if they
have pregnancy induced hypertension or mild preeclamp-
sia at a gestational age between 36+0 and 41+0 weeks of ges-
tation. A diagnosis of pregnancy induced hypertension is
made in case the diastolic BP is equal to or above 95
mmHg at two occasions at least six hours apart in a
woman who was normotensive at the start of pregnancy
until week 20 of gestational age. A diagnosis of mild
preeclampsia is made in case the diastolic BP is above 90
mmHg and there exists a proteinuria > 300 mg total pro-
tein in a 24 hour urine collection. Women with a single-
ton pregnancy in cephalic presentation are eligible.
Excluded were women with severe pregnancy induced
hypertension or preeclampsia (diastolic BP ≥ 110 mmHg,
systolic BP ≥ 170 mmHg and/or proteinuria ≥ 5 gram in
24 hours), pre-existing hypertension (BP before 20 weeks
of gestation ≥ 140/90 mmHg and/or using antihyperten-
sive medication), diabetes mellitus, diabetes gravidarum
requiring insulin therapy, renal disease, heart disease,
HIV-seropositivity, intravenous anti-hypertensive medica-
tion, a previous caesarean section, HELLP syndrome, olig-
uria < 500 milliliter in 24 hours, pulmonary edema or
cyanosis, fetal disorders, and abnormalities at the fetal
heart rate (FHR) -monitoring are not eligible for the study.
Procedures, recruitment, randomisation and collection of 
baseline data
Eligible women will be identified by the research coordi-
nator and/or the staff of participating hospitals. These
women will be referred to a research midwife or research
nurse for counselling. Before entry into the study this per-
son will explain to potential subjects the aims, methods,
reasonably anticipated benefits, and potential hazards of
the study. Subjects will be informed that their participa-
tion is voluntary and that they may withdraw consent to
participate at any time during the study. They will be
informed that choosing not to participate will not affect
their care. In every centre an independent gynaecologist
will be available for more detailed information both for
patients and colleagues if required. After giving sufficient
information written informed consent has to be obtained.
The consent form must be signed before performance of
any study-related activity. Patients who decide not to par-
ticipate in this study will be treated according to one of theBMC Pregnancy and Childbirth 2007, 7:14 http://www.biomedcentral.com/1471-2393/7/14
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two protocols at the discretion of the attending obstetri-
cian and analysed separately.
The study will be an open label study, as it is impossible
to blind the health care workers involved for the strategy
to which the woman is allocated. Cross-over between the
two strategies would complicate the interpretation of
study result. Although it will not be possible to prevent all
cross-overs, both strategies will be performed according to
strict criteria, as mentioned below.
After a patient has given informed consent for participa-
tion in the study cervical length will be measured using
transvaginal sonography, and vaginal examination will be
performed (Bishop score), both to assess cervical ripeness.
At study entry all women will have baseline demographic,
past obstetric and medical history recorded. After explana-
tion of the study and informed consent, but prior to ran-
domisation, we will perform a baseline measurement for
quality of life (SF-36, HADS, EuroQol 6D3L) and addi-
tional questions on intervention preparedness and per-
sonal experience of the pregnancy. Subsequently, the
patient will be randomised to either a policy that aims ter-
mination of pregnancy (intervention group) or a policy
that aims expectant management for spontaneous deliv-
ery (expectant group). Randomisation will be performed
through a web-based database which is hosted at the Aca-
demic Medical Centre (AMC) in Amsterdam. Randomisa-
tion will be 1:1 for intervention and expectant
management, and it will be stratified for centre, parity and
proteinuria according to the criteria above. Patients fill
out additional quality of life questionnaires 6 weeks after
delivery and 6 months after delivery (SF-36, HADS, Euro-
QoL 6D3L, SCL-90) and additional questions on personal
experience of the delivery.
At local centres data-collection will be the responsibility
of the local research coordinator and the regional research
midwives or nurses. The data collected in this study will




In the intervention group, patients will be induced
within 24 hours after randomisation. In patients with a
Bishop cervix score > 6 at vaginal examination labour will
be induced by amniotomy and, if needed, augmentation
with oxytocin. If this score is 6 or lower cervical ripening
will be stimulated with use of intracervical or intravaginal
prostaglandins according to the local protocol. In case the
cervix is judged to be unripe the day after 'priming', the
cervical ripening will be repeated. If the cervix remains
'unripe', day 3 will be a rest day. Cervical ripening will be
repeated at day 4 and 5. All patients in the intervention
group will be monitored clinically until after delivery.
Expectant group
In the expectant group, patients will be monitored until
the onset of spontaneous delivery. Monitoring will consist
of assessment of fetal movements as reported by the
mother, as well as electronic FHR-monitoring according
to the local protocol. Maternal evaluation consists prima-
rily of frequent evaluation of blood pressure measure-
ment and screening of urine for protein using a dipstick or
protein/creatinin ratio and 24 hour urine collection for
protein in case of positive screening. Blood tests (platelet
count, liver enzymes and renal function) will be per-
formed according to the local protocol.
In the expectant monitoring group, intervention is recom-
mended in case fetal condition does not justify expectant
management anymore (no fetal movements reported by
the mother, non-optimal FHR-monitoring). Moreover,
induction of labour is recommended in case the diastolic
blood pressure is ≥ 110 mmHg or the systolic blood pres-
sure is ≥ 170 mmHg, in case 24 hours proteinuria exceeds
5 gram, in case intravenous anti-hypertensive or prophy-
lactic anti-convulsive medication is started, in case
eclampsia or the HELLP syndrome occurs. In case in the
expectant group any other indication rises for induction
of labour, for example prelabour rupture of membranes
for > 24 hours or meconium stained liquor, patients will
be induced.
Follow up of women and infants
All details of delivery, maternal assessments and admis-
sion during pregnancy are recorded in the case record
form that is accessible through the website. Maternal mor-
tality and morbidity will be specified until date of dis-
charge from hospital and six weeks postpartum. In case of
admittance of the baby to the neonatal intensive care,
high care, medium care unit or maternal ward, details of
this admission are also documented. Neonatal mortality
and morbidity will be specified until date of discharge
from hospital. We will register the diagnosis at discharge:
small for gestational age, hypoglycemia, respiratory dis-
tress syndrome, chronic lung disease, meconium aspira-
tion, pneumothorax, apneu, asphyxia, necrotizing
enterocolitis, intraventicular hemorrhage, periventricular
leucomalacia, neonatal sepsis and neonatal meningitis.
A plan for long-term follow up of the mothers is in prep-
aration. Long-term follow up of children will not be per-
formed, because we do not expect differences between
both policies during childhood.BMC Pregnancy and Childbirth 2007, 7:14 http://www.biomedcentral.com/1471-2393/7/14
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Outcome measures
Primary outcome measure
The primary outcome measure will be severe maternal
morbidity, which can be complicated by maternal mortal-
ity in rare cases. Severe maternal morbidity will be defined
as diastolic BP ≥ 110 mmHg, systolic BP ≥ 170 mmHg,
major postpartum hemorrhage, eclampsia, HELLP syn-
drome, pulmonary edema, trombo-embolic disease and/
or abruptio placentae [14]. Major postpartum hemor-
rhage is defined as blood loss > 1000 ml within 24 hours
after delivery [15]. Eclampsia is defined as severe preg-
nancy induced hypertension or preeclampsia resulting in
maternal seizures [16]. HELLP syndrome is defined as a
complication of severe preeclampsia involving Hemoly-
sis, Elevated Liver functions, and Low Platelets [17].
Trombo-embolic disease is defined as deep-vein throm-
bosis, pulmonary embolism or both. Patients will be
examined for deep-vein thrombosis byduplex dopplerif
thrombosis is suspected from clinical examination. A
diagnosis of pulmonary embolism will be confirmed by
pulmonary angiography, computed tomography, mag-
netic resonance imaging or a ventilation-perfusion lung
scan [18-20].
Secondary outcome measures
Secondary outcomes will be neonatal mortality or neona-
tal morbidity, caesarean section rate, instrumental vaginal
delivery rate, maternal quality of life and quality of recov-
ery and costs. Adverse neonatal outcome will be defined
as a 5-minute Apgar score below 7, an umbilical artery pH
below 7.05 or admission to the neonatal intensive care.
Statistical issues
Sample size
The aim of induction of labour is to reduce the rate of
severe complications of hypertensive disease, such as
postpartum hemorrhage, sever hypertension (diastolic BP
≥ 110 mmHg), eclampsia and HELLP syndrome. In
women with a singleton pregnancy in cephalic presenta-
tion at term (>36 weeks), the prevalence of such compli-
cations in 2003 and 2004 was 12% [21]. To our opinion,
the disadvantages of induction of labour outweigh the
advantages when the complication rate is reduced to 6%.
In order to detect such a difference, we will need two
groups of 360 patients (two-sided test, alpha .05; beta
.80).
Data analysis
The analysis will be performed by intention to treat, and
stratified for centre, parity and for underlying disease
(preeclampsia or pregnancy induced hypertension).
Quality of life as well as pain scores will be analysed using
repeated measures analysis of variance [22]. Relative risks
and 95% confidence intervals will be calculated for the
relevant outcome measures.
Moreover, we will evaluate whether the relative benefits of
induction of labour will be stronger in women with a ripe
cervix at baseline and in women with a short cervical
length at transvaginal sonography. In case of equivalence
between outcomes, the analysis will be repeated on a par
protocol basis.
Economic analysis
The process of care is distinguished into three cost stages
(antenatal stage, delivery/childbirth, postnatal stage) and
three cost categories (direct medical costs [all costs in the
health care sector], direct non-medical costs [costs outside
the health care sector that are affected by health status or
health care] and indirect costs of the pregnant women and
her partner [costs of sick level]). For each stage and each
cost category, costs are measured as the volumes of
resources used multiplied with appropriate valuations
(cost-per-unit estimates, fees, national reference prices).
Cost volumes in the antenatal stage consist of direct med-
ical costs (e.g. home/hospital care, outpatients' visits, fetal
monitoring [FHR-monitoring, ultrasound, Doppler] and
maternal monitoring [various labtests; hospital care]).
Direct non-medical and indirect costs in that stage may
occur if role patterns or household routines shift. As we
anticipate an improvement of between maternal out-
comes after induction of labour the economic analysis is
expected to be a cost-effectiveness analysis.
Serious adverse events will be reported to an independ-
ent data safety monitoring committee. A formal interim
analysis is not planned.
Ethical considerations The study protocol has been
approved by the Medical Ethical Committee of the Uni-
versity Medical Centre of Leiden (p04.210). The protocol
is registered in the clinical trial register number
ISRCTN08132825.
Discussion
Pregnancy induced hypertension and preeclampsia are
important hypertensive disorders during pregnancy which
are associated with increased maternal and neonatal mor-
bidity and mortality. There is no consensus on how to
manage mild hypertensive diseases at term. Induction of
labour might prevent maternal complications, but is also
thought to increase the caesarean and vaginal instrumen-
tal delivery rate. This trial is designed to provide evidence
on the effectiveness of induction of labour in women with
mild pregnancy induced hypertension or preeclampsia
(nearly) at term to prevent severe maternal and neonatal
complications.Publish with BioMed Central    and   every 
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